Biomarker Market, By Product (Consumables and Services), By Disease Indication (Cancer, Cardiovascular disorders and Others), By Application (Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Trends, Analysis and Forecast till 2034

Biomarker Market was valued at US$ 90.2 Billion in 2024 and is projected to grow at a CAGR of 13.60% to reach US$ 288.5 Billion by 2034.

A biomarker is a trait that can be reliably examined and assessed as an indicator of a physiological or pathological process, as well as the pharmacological response to a therapeutic intervention. Biomarkers are useful not only for diagnosing diseases, but also for following their course, regression, and prognosis after treatment. Biomarkers include macromolecules such as carbohydrates, proteins, and lipids, as well as genes, DNA, RNA, platelets, enzymes, and hormones, among others. A biomarker can be anything that aids in the diagnosis of a disease, such as a metabolite, a change in biological structure, or a distinguishing feature. Biomarkers can be categorized in a variety of ways. Biomarkers can be found in tissue, blood, lymph, and bodily fluids, and they can be detected and evaluated (urine, stool, sputum, breast nipple aspiration, etc.). Exfoliated cells may contain biomarkers, as well as soluble or suspended materials (for example, proteins, DNA, and microRNA) in circulation or secretions. Finally, inherited germline biomarkers can be assessed using circulating leukocytes or exfoliated cells extracted from easily accessible tissues, such as a cheek swab. The biomarker are also used during the drug development process as the biomarker cut down the cost of the drug development process and the drug test by biomarker are considered for the clinical trials. As the Food and Drug Administration carries out the biomarker qualification program, where the qualified the potential to advance public health by encouraging efficiencies and innovation in drug development. Therefore, many biopharmaceutical, biotechnological industries and research institute are applying for biomarker qualification program. For instance, The Foundation for the National Institutes of Health Biomarkers Consortium (FNIH BC) Bone Quality have applied in 2016, for biomarker total hip bone mineral density.

                          For More Report Details, Download Free Sample PDF

Growing factors

Biomarkers are widely employed in fields like personalised medicine, companion diagnostics, and other diagnostic areas including drug discovery and development, as well as illness risk assessment.For Instance, The rising demand for personalized medicine, due to launch of precision medicine in U.S. in year 2015, by the President Obama with the aim to create the awareness regarding precision medicine. As precision medicine revolutionize the way of treatment to improve the health. Further, the precision medicine had invested US$215 Mn in the National Institute of Health in the fiscal budget of 2016, which is expected to foster the research on the discovery of biomarker, in turn supporting the growth of Biomarkers market.

 In the next years, market growth is likely to be fueled by biomarkers' expanding diagnostic applications. Biomarkers are important in personalised medicine because they can be used for diagnosis, prognosis, and the selection of targeted therapy. Because of the many limitations of normal diagnosis and treatment processes, personalised medicine has gained popularity throughout time. From cancer to immunological problems, several areas of medicine are moving toward personalised treatment for individual patients based on their genetic markers and clinical characteristics. Companion diagnostics and biomarkers have become increasingly important in medical practice, resulting in better diagnosis, treatment, and monitoring in a variety of illness areas.

Increasing research and expanding biotechnology

Further, the increasing research and expanding biotechnology and biopharmaceutical industries are also expected to favor the Biomarkers market. As according to 2012 EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sector represented 17.7% of business R&D expenditure globally.

Further, increasing prevalence of chronic diseases is expected to drive the Biomarkers market. For instance, according to the Centers for Disease Control and Prevention (CDC), 2015 data findings, 5,251 deaths were reported due to influenza infection in 2015, in the U.S. Furthermore, according to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease.

Restraining factors

Biomarker research, development, and validation necessitate large financial investments. This stifles the expansion of the biomarkers market, as well as adjacent markets like diagnostics (in vitro diagnostics or companion diagnostics) and tailored medications. Because of the inconsistency in their efficacy in illness diagnosis, validating biomarkers takes a long time. As a result, the validation procedure becomes both time-consuming and costly. Clinical trials and meeting tight regulatory criteria necessitate large costs, which not only limit small enterprises' ability to produce biomarkers but also stifle innovation. As a result, market expansion is hampered by both large capital inputs and a low cost-benefit ratio.

Biomarkers market is segmented based on product, disease indication, application and region.

On the basis of Product, the Biomarkers market is segmented into Consumables and Service. Based on Disease Indication, the target market is segmented into Cancer, Cardiovascular disorders and Others. By Application, the market is segmented into Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others.

Regional Insights:

On region the Biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the Biomarkers market. Increased R&D and expanding usage of biomarkers in personalized medicine and medication discovery and development are driving the biomarkers market in North America. Furthermore, due to the growing need for the detection and treatment of age-related disorders among the ageing population, North America has a well-established pharmaceuticals sector and dominates the biomarkers market. The Asia Pacific region is expected to show the fastest growth overall the region, due increasing prevalence of chronic disease, cancer and infectious disease. Further, with increasing investment in healthcare facilities by government also favors the growth of biomarker market in Asia Pacific region. Further, the Middle East and Africa are untapped region, which provides opportunity to the local players to penetrate within the market of biomarker market in Middle East region, with low price of biomarker test.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Biomarkers Market report based on Product, Disease Indication, Application and region:

Biomarkers Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the Biomarkers market includes EKF Diagnostics Holdings, Inc., Meso Scale Diagnostics, LLC., Biosims Technologies Sac, Cisbio Bioassays, Signosis, Inc. Qiagen N.V., Perkinelmer, Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc. and Others.

• EKF Diagnostic Holdings Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Meso Scale Diagnostics, LLC.
• Biosims Technologies Sac
• Cisbio Bioassays
• Signosis, Inc.
• Qiagen N.V.
• Perkinelmer, Inc.
• Merck Millipore
• Bio-Rad Laboratories, Inc.
• Enzo Biochem, Inc.
• Others.

“*” marked represents similar segmentation in other categories in the respective section